Exact Sciences Corporation (EXAS) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects strong financial performance with raised revenue and EBITDA guidance, a solid productivity plan, and promising product developments like Cologuard Plus and Cancerguard. The Q&A section highlights ongoing payer negotiations and future growth potential, despite some uncertainties in timelines and pricing strategies. The overall sentiment is positive, supported by optimistic guidance and strategic initiatives aimed at long-term growth.
Key Financial Performance
Total Revenue $851 million, a 20% year-over-year increase. This growth was driven by Cologuard's strong brand awareness, commercial execution, health systems integrations, and a record number of ordering providers.
Screening Revenue $666 million, a 22% year-over-year increase. Growth was led by broad-based Cologuard growth, care gap programs, and rescreens.
Precision Oncology Revenue $183 million, a 12% year-over-year increase on a core basis. Growth was driven by Oncotype DX expansion internationally, U.S. Oncotype DX volumes, and partner revenues.
Adjusted EBITDA $135 million, a 37% year-over-year increase. Adjusted EBITDA margins expanded by 200 basis points to 16%, driven by efficiency efforts across lab, supply chain, G&A, and support functions.
Non-GAAP Gross Margins 71%, down 100 basis points year-over-year. The reduction was due to record care gap shipments causing a temporary timing difference between cost of goods and revenue.
Free Cash Flow $190 million, a $77 million increase year-over-year. This was driven by increased receivables collections following the Cologuard Plus launch and working capital improvements.
Year-to-Date Free Cash Flow $236 million, a $173 million or 270% year-over-year increase. This was attributed to improved receivables collections and working capital improvements.
Cash and Securities Just over $1 billion at the end of the quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Cancerguard launch: Introduced Cancerguard, a multi-cancer early detection test screening for over 50 cancer types and subtypes. Leveraging multiple channels for adoption, including primary care physicians, health systems, and a consumer-initiated ordering platform. Direct-to-consumer marketing campaigns initiated.
Cologuard Plus: Expanded access to Cologuard Plus with positive coverage decisions from top 10 payers. Demonstrated 95% sensitivity and 94% specificity, reducing false positives by 40% compared to the original Cologuard.
Oncodetect: Launched MRD test Oncodetect, showing encouraging utilization in colorectal and breast cancer.
Cologuard brand awareness: Achieved over 90% consumer recognition, driving adoption among 55 million Americans not up-to-date with colorectal cancer screening.
Precision Oncology expansion: Oncotype DX saw international growth and expanded screening guidelines to younger age groups.
Revenue growth: Total revenue grew 20% year-over-year to $851 million, with screening revenue up 22% and Precision Oncology revenue up 12%.
Adjusted EBITDA: Increased 37% year-over-year to $135 million, with margins expanding by 200 basis points to 16%.
Free cash flow: Increased to $190 million, up $77 million year-over-year, driven by receivables collections and working capital improvements.
Consumer-initiated orders (CIO): Enabled individuals to request tests online via telehealth, driving triple-digit growth in this demographic.
R&D investments: Focused on multi-omic platform advancements, including liver, esophageal, and endometrial cancer tests. Presented ONCOGUARD liver data and planned further clinical validation studies for MRD tests.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Non-GAAP gross margins: Gross margins decreased by 100 basis points compared to the previous year, driven by record care gap shipments. This indicates potential cost pressures and timing mismatches between costs and revenue.
Freenome licensing agreement: The upfront payment of $75 million for the Freenome licensing agreement will be expensed to R&D upon clearance of HSR, which could impact short-term financials and adjusted EBITDA.
Cologuard rescreens: Rescreens now represent more than 25% of total screening volume, but maintaining this recurring revenue stream requires consistent patient engagement and trust in the product.
Cancerguard launch: The launch of Cancerguard, a multi-cancer early detection test, involves significant investment in direct-to-consumer marketing and training of sales teams, which could strain resources and require time to achieve profitability.
Pipeline investments: Investments in R&D for new tests like Oncodetect and ONCOGUARD liver require substantial funding and carry risks related to clinical validation, regulatory approval, and market adoption.
Precision Oncology portfolio: While showing positive momentum, the portfolio's growth depends on effective commercial execution and adoption of new products like Oncodetect, which may face competitive and market challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year 2025 Revenue Guidance: Raised to between $3.22 billion and $3.235 billion, reflecting an increase of $78 million at midpoint.
Screening Revenue Guidance: Expected to be between $2.51 billion and $2.52 billion, representing 20% growth at midpoint.
Precision Oncology Revenue Guidance: Projected to be between $710 million and $715 million, reflecting 9% growth at midpoint.
Adjusted EBITDA Guidance: Increased to between $470 million and $480 million for the full year, implying 47% growth and 300 basis points of margin expansion.
Cancerguard Launch and Adoption: The multi-cancer early detection test, Cancerguard, was launched in Q3 2025. Plans include training the entire U.S. commercial team by year-end and investing in direct-to-consumer marketing starting in Q4 2025.
Oncodetect Development: Clinical validation data for the next-generation version of Oncodetect leveraging MAESTRO technology is expected in 2026.
MRD Evidence Generation: Over 10 clinical validation studies planned over the next few years, including 4 key studies in breast cancer, colorectal cancer, and pan-tumor indications.
Oncoguard Liver Test: Data from the ALTUS study to be presented at the American Association for the Study of Liver Diseases meeting, highlighting its potential for liver cancer surveillance.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What drove the remarkable performance in the third quarter for screening?
A:The team deepened relationships with health systems, designed territories for better targeting, and improved messaging. The ExactNexus platform and new products also contributed to the success. Leadership and the frontline sales force played a significant role in achieving growth.
Q:How is the company pacing for 2026 screening growth?
A:The company is pacing ahead of its long-term goal of a 15% compounded annual growth rate from 2022 through 2027. The full-year guide for screening is at 20%, with the back half of the year exceeding that. Specific 2026 guidance will be provided at the next earnings call.
Q:What is the outlook for care gap strength and its impact on margins?
A:The care gap program had a record quarter with significant volume growth. While it has slightly lower gross margins, it is highly accretive to the bottom line. Gross margins are expected to improve in Q4 as fewer care gap shipments are anticipated.
Q:What is the strategy for Cancerguard with payers and reimbursement?
A:Cancerguard is priced at $689 and is distinct from other Medicare-covered tests. The company believes in keeping tests separate for Medicare populations and is working on gaining coverage across Medicare and commercial payers. The approach is seen as a long-term effort to demonstrate the positive impact of screening.
Q:What are the timelines and updates for Freenome V2 and the internal program?
A:Freenome V2 data is expected to be presented in conjunction with a scientific conference in the next few months. The internal program continues, and the Freenome test is now the Exact test. The company is preparing to make the blood test available to physicians and patients, subject to regulatory approvals.
Q:What is the plan for transitioning from Cologuard to Cologuard Plus?
A:The company plans to sunset Cologuard next year, making Cologuard Plus the only test available. Cologuard Plus has superior sensitivity and specificity, and discussions with payers are ongoing. Four of the top 10 payers have contracted, and discussions with six others are in progress.
Q:Are new products like Oncodetect and Cancerguard material contributors in 2025?
A:The company does not expect these products to be material contributors in 2025 but sees them as significant long-term opportunities. Cancerguard has shown promising growth since its recent launch, and Oncodetect is progressing with scientific evidence to secure broad coverage.
Q:What was the contribution of Cologuard Plus to screening growth in the quarter?
A:Cologuard Plus contributed 200 to 300 basis points to screening growth in Q3. With additional payer contracts, the contribution is expected to increase to 300 to 400 basis points in Q4. The company is in active discussions with remaining top payers.
Q:How is care gap compliance progressing?
A:Care gap compliance shows room for improvement. The company is seeing significant year-over-year volume increases and is working to improve compliance rates. Many payers and health systems are converting to Cologuard due to its compliance engine and longer screening duration.
Q:When will the remaining six commercial payers contract for Cologuard Plus?
A:The company is making strong progress with the remaining six payers but has not provided specific timelines. The goal is to eventually sunset Cologuard and move all patients to the newer and better test.
Q:What is the pricing strategy for CRC blood tests?
A:The pricing strategy has not been finalized. The company aims to secure broad access and impact, balancing sensitivity, access, and compliance. The goal is to bring value to patients, payers, and the healthcare ecosystem.
Q:What is the progress on the $150 million cost savings program?
A:The program is progressing well, with actions taken to deliver $150 million in savings by 2026. Onetime expenses are expected to be lower than initially guided, with approximately $85 million anticipated for this year.
Q:What is the updated view on rescreening penetration?
A:Rescreening penetration is in the mid-50s to high 50s. The company aims to automate the rescreen process to achieve 70% to 75% penetration over time. The focus is on securing prescriptions to drive compliance.
Q:How does the telehealth ordering process integrate with primary care physicians?
A:The ExactNexus platform, powered by Epic, integrates telehealth orders with electronic medical records. This ensures that physicians receive credit for screenings and allows for population-level health management.
Q:What is the impact of care gap programs on gross margins?
A:Care gap programs, which are back-end loaded, slightly lower gross margins. However, gross margins are expected to improve in Q4 and Q1 of 2026 as fewer care gap shipments are anticipated.
Q:What is the outlook for Oncodetect as a material contributor?
A:Oncodetect is not expected to be material this year but is seen as a long-term opportunity. The company is focused on generating clinical evidence to support adoption and coverage.
Q:What is the update on Freenome's simple screen and its commercialization?
A:Freenome V2 data is expected in the next few months, with pivotal data coming next year. The company has exclusive rights to market the CRC blood screening test and plans to use its database and relationships to target appropriate patients.
Q:What is the role of the PCP commercial infrastructure in Cancerguard's launch?
A:The PCP commercial infrastructure is expected to play a significant role in identifying patients willing to pay for Cancerguard. The company's relationships with health systems and its reputation for quality and service are also key advantages.
Q:What is the contribution of Oncotype DX to Precision Oncology growth?
A:Oncotype DX continues to expand in international markets and showed a volume increase in the U.S., contributing to double-digit growth in the Precision Oncology business.
Q:What is the company's approach to CRC blood test launch and patient targeting?
A:The company plans to use its database to identify patients who have refused other screening methods and target them with the CRC blood test. The goal is to get the right test to the right patient at the right time.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines for contracting the remaining six commercial payers for Cologuard Plus. They also did not finalize or disclose the pricing strategy for CRC blood tests. Additionally, no material updates were given on the internal program for Freenome V2 beyond its continuation.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO Exact
Cancerguard detection
Chairman CEO
Cologuard care
DX expansion
DX volume
HSR add
Leckow today
Momentum leverage
Non basis
Oncology basis
Plus adoption
RD clearance
Relations Exact
access Cologuard
add inflection
afternoon midpoint
agreement payment
awareness health
basis Oncotype
care gap
cash flow
clearance HSR
collection Cologuard
difference cost
effectiveness access
efficiency effort
effort lab
expansion Freenome
expansion Oncotype
figure
flow increase
function Non
gap guideline
gap shipment
generation target
news release
record
statement
website
EXAS Transcript
Exact Sciences Corporation (EXAS) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neutral11-18
Exact Sciences Corporation (EXAS) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call reflects strong financial performance with raised revenue and EBITDA guidance, a solid productivity plan, and promising product developments like Cologuard Plus and Cancerguard. The Q&A section highlights ongoing payer negotiations and future growth potential, despite some uncertainties in timelines and pricing strategies. The overall sentiment is positive, supported by optimistic guidance and strategic initiatives aimed at long-term growth.
Exact Sciences Corporation (EXAS) Presents At Baird 2025 Global Healthcare Conference (Transcript)
Neutral9-9
Exact Sciences Corporation (EXAS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Neutral9-3
EXAS Slides
EXAS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
